About Actemra

General Information of Actemra:

ACTEMRA is a prescription medicine called an Interleukin-6 (IL-6) receptor antagonist.

ACTEMRA is used:

To treat adults with moderately to severely active rheumatoid arthritis (RA), after at least one other medicine called a Disease-Modifying Anti-Rheumatic Drug (DMARD) has been used and did not work well.
To treat adults with giant cell arteritis (GCA).
For slowing the rate of decline in lung function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD) (also known as scleroderma associated ILD).
To treat people with active PJIA ages 2 and above.
To treat people with active SJIA ages 2 and above.
To treat people age 2 years and above who experience severe or life-threatening Cytokine Release Syndrome (CRS) following chimeric antigen receptor (CAR) T cell treatment.
To treat hospitalized adults with coronavirus disease 2019 (COVID-19) receiving systemic corticosteroids and requiring supplemental oxygen or mechanical ventilation.
ACTEMRA is not approved for subcutaneous use in people with CRS or COVID-19.

It is not known if ACTEMRA is safe and effective in children with PJIA, SJIA, or CRS under 2 years of age or in children with conditions other than PJIA, SJIA or CRS.